Human Chronic Lymphoid Leukemia Bone Marrow CD19+/CD5+ B Cells, Untreated

Description

Human Chronic Lymphoid Leukemia (CLL) Bone Marrow CD19+/CD5+ B Cells, Untreated are isolated from the bone marrow aspirates of untreated CLL patients. These cells represent a malignant subset of B lymphocytes characterized by co-expression of CD19 and CD5 surface antigens. Cells are cryopreserved after initial isolation. Morphologically, CLL B cells exhibit a small, mature lymphocyte appearance with scant cytoplasm and a condensed nucleus. These cells grow in suspension and do not proliferate under in vitro conditions without mitogenic stimulation. CD19+/CD5+ CLL B cells play a key role in the disease’s progression, immune evasion, and interaction with the tumor microenvironment. Phenotypically, these cells show strong expression of CD19, CD5, and CD20. Cytogenetic analysis often reveals genomic aberrations such as del(13q), del(11q), or trisomy 12, typical of CLL pathogenesis. Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.